Literature DB >> 8561091

Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients.

U C Nzeako1, Z D Goodman, K G Ishak.   

Abstract

This study examined clinico-histopathologic differences between North American patients who developed hepatocellular carcinoma with and without cirrhosis. Histologic slides and clinical records of cases were reviewed. Cases were classified according to defined histopathologic criteria. Analyses were performed using appropriate tests. A total of 42.6% of cases were noncirrhotic. The trabecular type of hepatocellular carcinoma was the most common growth pattern in both groups. Patients with cirrhosis were significantly older, had high grade tumors, and local portal venous invasion significantly more often than patients without cirrhosis. Encapsulated tumors occurred in significantly more in patients without cirrhosis. Patients without cirrhosis survived longer than patients with cirrhosis (P < .0001) and had a better 5-year survival experience. On average, in patients with cirrhosis, serum aspartate transaminase and total serum bilirubin were significantly greater, and serum albumin was significantly lower. In general, hepatocellular carcinoma in North American patients with cirrhosis tended to be less well differentiated than those found among patients without cirrhosis. The pathology, natural history, and prognosis of this tumor is significantly influenced by the presence or absence of cirrhosis in the nonneoplastic liver, and the presence of cirrhosis portends a poorer prognosis.

Entities:  

Mesh:

Year:  1996        PMID: 8561091     DOI: 10.1093/ajcp/105.1.65

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  44 in total

Review 1.  Hepatocellular carcinoma: updates in primary prevention.

Authors:  Will J Fecht; Alex S Befeler
Journal:  Curr Gastroenterol Rep       Date:  2004-02

2.  Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population.

Authors:  Min Jung Park; Young-Sun Kim; Won Jae Lee; Hyo K Lim; Hyunchul Rhim; Jongmee Lee
Journal:  Eur Radiol       Date:  2010-06-19       Impact factor: 5.315

3.  Platelet-related phenotypic patterns in hepatocellular carcinoma patients.

Authors:  Brian I Carr; Chih-Yun Lin; Sheng-Nan Lu
Journal:  Semin Oncol       Date:  2014-04-23       Impact factor: 4.929

4.  Tumor of the liver (hepatocellular and high grade neuroendocrine carcinoma): a case report and review of the literature.

Authors:  Monica T Garcia; Pablo A Bejarano; Maria Yssa; Efren Buitrago; Alan Livingstone
Journal:  Virchows Arch       Date:  2006-08-01       Impact factor: 4.064

5.  Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation.

Authors:  Rajesh Kannangai; Jianzhou Wang; Qiong Z Liu; Fikret Sahin; Michael Torbenson
Journal:  Int J Gastrointest Cancer       Date:  2005

Review 6.  Liver cancer screening in high-risk populations.

Authors:  Morris Sherman
Journal:  Hepat Oncol       Date:  2015-11-30

Review 7.  Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols.

Authors:  Danijel Galun; Dragan Basaric; Marinko Zuvela; Predrag Bulajic; Aleksandar Bogdanovic; Nemanja Bidzic; Miroslav Milicevic
Journal:  World J Hepatol       Date:  2015-09-18

8.  Hepatocellular Carcinoma Without Cirrhosis Presenting With Hypercalcemia: Case Report and Literature Review.

Authors:  Neil B Newman; Salma K Jabbour; Jane Date C Hon; Joseph J Berman; Deen Malik; Darren Carpizo; Rebecca A Moss
Journal:  J Clin Exp Hepatol       Date:  2015-04-18

9.  Microvessel density and clinicopathologic characteristics in hepatocellular carcinoma with and without cirrhosis.

Authors:  Ivan Chebib; Meer Taher Shabani-Rad; Michelle S Chow; James Zhang; Zu-Hua Gao
Journal:  Biomark Insights       Date:  2007-02-14

10.  Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.

Authors:  Giuseppe Di Lorenzo; Antonio Rea; Chiara Carlomagno; Stefano Pepe; Giovannella Palmieri; Roberto Labianca; Antonio Chirianni; Alfonso De Stefano; Vincenzo Esposito; Sabino De Placido; Vincenzo Montesarchio
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.